AbbVie (NYSE:ABBV) Updates Q2 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its second quarter 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 3.740-3.780 for the period, compared to the consensus earnings per share estimate of 3.740. The company issued revenue guidance of $16.7 billion-$16.7 billion, compared to the consensus revenue estimate of $16.8 billion.

AbbVie Trading Down 2.2%

Shares of ABBV traded down $4.69 during midday trading on Friday, reaching $206.63. 6,339,492 shares of the stock were exchanged, compared to its average volume of 7,231,846. AbbVie has a 52 week low of $176.57 and a 52 week high of $244.81. The company’s 50 day moving average is $214.55 and its two-hundred day moving average is $221.60. The company has a market capitalization of $365.36 billion, a P/E ratio of 101.79, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the company earned $2.46 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. On average, sell-side analysts expect that AbbVie will post 14.13 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is presently 293.22%.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent research reports. Guggenheim reaffirmed a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research report on Friday. Royal Bank Of Canada initiated coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. Evercore dropped their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Canaccord Genuity Group raised their price objective on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday. Finally, William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $252.90.

Insider Transactions at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by company insiders.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

Institutional Investors Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp raised its stake in AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after buying an additional 1,119,274 shares during the last quarter. Bank of America Corp DE raised its stake in AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after buying an additional 356,394 shares during the last quarter. Wellington Management Group LLP raised its stake in AbbVie by 41.7% in the fourth quarter. Wellington Management Group LLP now owns 14,926,683 shares of the company’s stock valued at $3,410,598,000 after buying an additional 4,389,782 shares during the last quarter. Amundi raised its stake in AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after buying an additional 1,414,621 shares during the last quarter. Finally, Raymond James Financial Inc. raised its stake in AbbVie by 2.4% in the third quarter. Raymond James Financial Inc. now owns 9,557,701 shares of the company’s stock valued at $2,212,110,000 after buying an additional 220,221 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.